{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:34:03Z","timestamp":1781105643788,"version":"3.54.1"},"reference-count":108,"publisher":"Japanese Society for Pediatric Endocrinology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pediatr Endocrinol"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1297\/cpe.2024-0058","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T18:10:32Z","timestamp":1729879832000},"page":"01-12","source":"Crossref","is-referenced-by-count":2,"title":["Current understanding and perspectives on growth and long-acting GH therapy          in Japan"],"prefix":"10.1297","volume":"34","author":[{"given":"Yukihiro","family":"Hasegawa","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Tokyo Metropolitan Children\u2019s              Medical Center, Tokyo, Japan"},{"name":"Department of Pediatrics, Keio University School of Medicine, Tokyo,              Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Ikegawa","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Tokyo Metropolitan Children\u2019s              Medical Center, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Mitani-Konno","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Tokyo Metropolitan Children\u2019s              Medical Center, Tokyo, Japan"},{"name":"Department of Pediatrics, Keio University School of Medicine, Tokyo,              Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ariyasu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Keio University School of Medicine, Tokyo,              Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Amano","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Tokyo Metropolitan Children\u2019s              Medical Center, Tokyo, Japan"},{"name":"Department of Pediatrics, Keio University School of Medicine, Tokyo,              Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"125","reference":[{"key":"1","unstructured":"1. Christiansen,                JS,                Backeljauw,              PF,                Bidlingmaier,              M, Biller,                BM,                Boguszewski,              MC,              Casanueva,            FF, et al.            Growth Hormone Research Society perspective on the development of            long-acting growth hormone preparations. Eur J            Endocrinol          2016;174: C1\u20138."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Yuen,              KCJ, Miller,                BS, Biller,                BMK. The            current state of long-acting growth hormone preparations for growth hormone            therapy. Curr Opin Endocrinol Diabetes Obes          2018;25: 267\u201373.","DOI":"10.1097\/MED.0000000000000416"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Miller,              BS,              Velazquez, E,                Yuen,            KCJ. Long-acting            growth hormone preparations - current status and future considerations.            J Clin Endocrinol Metab          2020;105: e2121\u201333.","DOI":"10.1210\/clinem\/dgz149"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Yuen,              KCJ, Miller,                BS,                Boguszewski,              CL, Hoffman,                AR.            Usefulness and potential pitfalls of long-acting growth hormone            analogs. Front Endocrinol (Lausanne)          2021;12: 637209.","DOI":"10.3389\/fendo.2021.637209"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Miller,              BS. What do we            do now that the long-acting growth hormone is here? Front            Endocrinol (Lausanne)          2022;13: 980979.","DOI":"10.3389\/fendo.2022.980979"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. H\u00f6ybye,              C. Comparing            treatment with daily and long-acting growth hormone formulations in adults with growth            hormone deficiency: Challenging issues, benefits, and risks.            Best Pract Res Clin Endocrinol Metab          2023;37: 101788.","DOI":"10.1016\/j.beem.2023.101788"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. \u00c7etinkaya,                S, Eren,                E, Erdo\u011fan,                F,                Darendeliler,              F. Long-acting            Growth Hormone Therapy, Rational and Future Aspects. J Clin Res            Pediatr Endocrinol          2024; Epub ahead of print.","DOI":"10.4274\/jcrpe.galenos.2024.2023-11-8"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Yang,              Y, Bai,                X, Yuan,                X, Zhang,                Y, Chen,                S, Yang,                H, et al.            Efficacy and safety of long-acting growth hormone in children with short            stature: a systematic review and meta-analysis.            Endocrine          2019;65: 25\u201334.","DOI":"10.1007\/s12020-019-01950-9"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Mameli,              C, Orso,                M,                Calcaterra,              V,              Wasniewska,              MG, Aversa,                T, Granato,                S, et al.            Efficacy, safety, quality of life, adherence and cost-effectiveness of            long-acting growth hormone replacement therapy compared to daily growth hormone in            children with growth hormone deficiency: A systematic review and            meta-analysis. Pharmacol Res          2023;193: 106805.","DOI":"10.1016\/j.phrs.2023.106805"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Zhu,              J, Yuan,                K, Rana,                S, Jakki,                SL, Bhat,                AS, Liang,                L, et al.            Long-acting growth hormone in the treatment of growth hormone deficiency            in children: a systematic literature review and network meta-analysis.            Sci Rep          2024;14: 8061.","DOI":"10.1038\/s41598-024-58616-4"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Velazquez,                EP, Miller,                BS, Yuen,                KCJ.            Somatrogon injection for the treatment of pediatric growth hormone            deficiency with comparison to other LAGH products. Expert Rev            Endocrinol Metab          2024;19: 1\u201310.","DOI":"10.1080\/17446651.2023.2290495"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Tanaka,              T. History of            GH treatment in Japan. Clin Pediatr Endocrinol          2022;31: 1\u20139.","DOI":"10.1297\/cpe.2021-0044"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Messina,                MF, De              Luca, F,                Wasniewska,              M, Valenzise,                M,              Lombardo, F,                Ghizzoni,            L. Final height            in isolated GH deficiency type 1A: effects of 5-year treatment with            IGF-I. Eur J Endocrinol          2001;144: 379\u201383.","DOI":"10.1530\/eje.0.1440379"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Caster\u00e0s,                A,              Kratzsch, J,                Ferr\u00e1ndez,              A, Zaf\u00f3n,                C,                Carrascosa,              A, Mesa,                J. Clinical            challenges in the management of isolated GH deficiency type IA in            adulthood. Endocrinol Diabetes Metab Case Rep          2014;2014: 130057.","DOI":"10.1530\/EDM-13-0057"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Braga,              S, Phillips,                JA, Joss,                E, Schwarz,                H,                Zuppinger,              K. Familial            growth hormone deficiency resulting from a 7.6 kb deletion within the growth hormone            gene cluster. Am J Med Genet          1986;25: 443\u201352.","DOI":"10.1002\/ajmg.1320250306"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ghizzoni,                L,                Duquesnoy,              P, Torresani,                T, Vottero,                A,              Goossens, M,                Bernasconi,              S. Isolated            growth hormone deficiency type IA associated with a 45-kilobase gene deletion within the            human growth hormone gene cluster in an Italian family. Pediatr            Res          1994;36: 654\u20139.","DOI":"10.1203\/00006450-199411000-00021"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ghizzoni,                L,                Duquesnoy,              P, Torresani,                T, Vottero,                A,              Goossens, M,                Bernasconi,              S. Isolated            growth hormone deficiency type IA associated with a 45-kilobase gene deletion within the            human growth hormone gene cluster in an Italian family. Pediatr            Res          1994;36: 654\u20139.","DOI":"10.1203\/00006450-199411000-00021"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Goossens,                M, Brauner,                R,                Czernichow,              P, Duquesnoy,                P,                Rappaport,              R. Isolated            growth hormone (GH) deficiency type 1A associated with a double deletion in the human GH            gene cluster. J Clin Endocrinol Metab          1986;62: 712\u20136.","DOI":"10.1210\/jcem-62-4-712"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Godowski,                PJ, Leung,                DW,              Meacham, LR,                Galgani,            JP, Hellmiss,                R, Keret,                R, et al.            Characterization of the human growth hormone receptor gene and            demonstration of a partial gene deletion in two patients with Laron-type            dwarfism. Proc Natl Acad Sci USA          1989;86: 8083\u20137.","DOI":"10.1073\/pnas.86.20.8083"},{"key":"20","unstructured":"20. Berg,              MA, Argente,                J,                Chernausek,              S, Gracia,                R,                Guevara-Aguirre,              J, Hopp,                M, et al.            Diverse growth hormone receptor gene mutations in Laron            syndrome. Am J Hum Genet          1993;52: 998\u20131005."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Guevara-Aguirre,                J,                Rosenbloom,              AL, Fielder,                PJ,              Diamond, FB,                Rosenfeld,              RG. Growth            hormone receptor deficiency in Ecuador: clinical and biochemical phenotype in two            populations. J Clin Endocrinol Metab          1993;76: 417\u201323.","DOI":"10.1210\/jcem.76.2.7679400"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Berg,              MA,                Guevara-Aguirre,              J,              Rosenbloom,              AL,              Rosenfeld,            RG, Francke,                U. Mutation            creating a new splice site in the growth hormone receptor genes of 37 Ecuadorean            patients with Laron syndrome. Hum Mutat          1992;1: 24\u201332.","DOI":"10.1002\/humu.1380010105"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Rosenbloom,                AL, Guevara                Aguirre, J,                Rosenfeld,              RG, Fielder,                PJ. The            little women of Loja--growth hormone-receptor deficiency in an inbred population of            southern Ecuador. N Engl J Med          1990;323: 1367\u201374.","DOI":"10.1056\/NEJM199011153232002"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Rosenfeld,                RG,                Rosenbloom,              AL,                Guevara-Aguirre,              J. Growth            hormone (GH) insensitivity due to primary GH receptor deficiency.            Endocr Rev          1994;15: 369\u201390.","DOI":"10.1210\/edrv-15-3-369"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Woods,              KA,                Camacho-H\u00fcbner,              C, Savage,                MO, Clark,                AJ.            Intrauterine growth retardation and postnatal growth failure associated            with deletion of the insulin-like growth factor I gene. N Engl J            Med          1996;335: 1363\u20137.","DOI":"10.1056\/NEJM199610313351805"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Walenkamp,                MJ,                Karperien,              M, Pereira,                AM,                Hilhorst-Hofstee,              Y, van Doorn,                J, Chen,                JW, et al.            Homozygous and heterozygous expression of a novel insulin-like growth            factor-I mutation. J Clin Endocrinol Metab          2005;90: 2855\u201364.","DOI":"10.1210\/jc.2004-1254"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Baxter,              RC.            Insulin-like growth factor binding proteins in the human circulation: a            review. Horm Res          1994;42: 140\u20134.","DOI":"10.1159\/000184186"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Domen\u00e9,              HM, Mart\u00ednez,                AS,              Frystyk, J,                Bengolea,              SV, Ropelato,                MG,              Scaglia, PA,              et al. Normal growth spurt and final height            despite low levels of all forms of circulating insulin-like growth factor-I in a patient            with acid-labile subunit deficiency. Horm Res          2007;67: 243\u20139.","DOI":"10.1159\/000098479"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Domen\u00e9,              HM, Hwa,                V, Jasper,                HG,                Rosenfeld,              RG. Acid-labile            subunit (ALS) deficiency. Best Pract Res Clin Endocrinol            Metab          2011;25: 101\u201313.","DOI":"10.1016\/j.beem.2010.08.010"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Werther,                GA, Haynes,                KM,              Barnard, R,                Waters,            MJ. Visual            demonstration of growth hormone receptors on human growth plate            chondrocytes. J Clin Endocrinol Metab          1990;70: 1725\u201331.","DOI":"10.1210\/jcem-70-6-1725"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. D\u2019Ercole,                AJ, Stiles,                AD,                Underwood,              LE. Tissue            concentrations of somatomedin C: further evidence for multiple sites of synthesis and            paracrine or autocrine mechanisms of action. Proc Natl Acad Sci            USA          1984;81: 935\u20139.","DOI":"10.1073\/pnas.81.3.935"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Miller,              BS, Rogol,                AD,                Rosenfeld,              RG. The history            of the insulin-like growth factor system. Horm Res            Paediatr          2022;95: 619\u201330.","DOI":"10.1159\/000527123"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Rao,              E, Weiss,                B, Fukami,                M, Rump,                A, Niesler,                B, Mertz,                A, et al.            Pseudoautosomal deletions encompassing a novel homeobox gene cause growth            failure in idiopathic short stature and Turner syndrome. Nat            Genet          1997;16: 54\u201363.","DOI":"10.1038\/ng0597-54"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34. Rousseau,                F,                Bonaventure,              J,                Legeai-Mallet,              L, Pelet,                A, Rozet,                JM,                Maroteaux,              P, et al.            Mutations in the gene encoding fibroblast growth factor receptor-3 in            achondroplasia. Nature          1994;371: 252\u20134.","DOI":"10.1038\/371252a0"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Bellus,              GA, McIntosh,                I, Smith,                EA,                Aylsworth,              AS, Kaitila,                I, Horton,                WA, et al.            A recurrent mutation in the tyrosine kinase domain of fibroblast growth            factor receptor 3 causes hypochondroplasia. Nat Genet          1995;10: 357\u20139.","DOI":"10.1038\/ng0795-357"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Myers,              A, Bernstein,                JA,              Brennan, ML,                Curry, C,                Esplin, ED,                Fisher, J,              et al. Perinatal features of the            RASopathies: Noonan syndrome, cardiofaciocutaneous syndrome and Costello            syndrome. Am J Med Genet A          2014;164A: 2814\u201321.","DOI":"10.1002\/ajmg.a.36737"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Lui,              JC, Nilsson,                O, Baron,                J. Recent            research on the growth plate: Recent insights into the regulation of the growth            plate. J Mol Endocrinol          2014;53: T1\u20139.","DOI":"10.1530\/JME-14-0022"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Brod,              M, Alolga,                SL, Beck,                JF,                Wilkinson,              L, H\u00f8jbjerre,                L,                Rasmussen,              MH.            Understanding burden of illness for child growth hormone            deficiency. Qual Life Res          2017;26: 1673\u201386.","DOI":"10.1007\/s11136-017-1529-1"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Rosenfeld,                RG, Bakker,                B. Compliance            and persistence in pediatric and adult patients receiving growth hormone            therapy. Endocr Pract          2008;14: 143\u201354.","DOI":"10.4158\/EP.14.2.143"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Cutfield,                WS,              Derraik, JG,                Gunn, AJ,                Reid, K,                Delany, T,                Robinson,            E, et al.            Non-compliance with growth hormone treatment in children is common and            impairs linear growth. PLoS One          2011;6: e16223.","DOI":"10.1371\/journal.pone.0016223"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Hughes,              IP, Choong,                C, Rath,                S,              Atkinson, H,                Cotterill,              A, Cutfield,                W, et al.            Early cessation and non-response are important and possibly related            problems in growth hormone therapy: An OZGROW analysis. Growth            Horm IGF Res          2016;29: 63\u201370.","DOI":"10.1016\/j.ghir.2016.04.006"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. van                Dommelen, P,                Koledova,            E, Wit,                JM. Effect of            adherence to growth hormone treatment on 0-2 year catch-up growth in children with            growth hormone deficiency. PLoS One          2018;13: e0206009.","DOI":"10.1371\/journal.pone.0206009"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Los,              E, Rosenfeld,                RG. Growth            and growth hormone in Turner syndrome: Looking back, looking ahead.            Am J Med Genet C Semin Med Genet          2019;181: 86\u201390.","DOI":"10.1002\/ajmg.c.31680"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Deal,              CL, Tony,                M, H\u00f6ybye,                C, Allen,                DB, Tauber,                M,                Christiansen,              JS, 2011 Growth            Hormone in Prader-Willi Syndrome Clinical Care Guidelines Workshop            Participants.GrowthHormone Research Society workshop            summary: consensus guidelines for recombinant human growth hormone therapy in            Prader-Willi syndrome. J Clin Endocrinol Metab          2013;98: E1072\u201387.","DOI":"10.1210\/jc.2012-3888"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Yamada,              M, Fujii,                K,              Hasegawa, T,                Hasegawa,            Y. Serum            acid-labile subunit is a good parameter for diagnosis of GH deficiency.            Clin Pediatr Endocrinol          1997;6(Supple 9):            99\u2013101.","DOI":"10.1297\/cpe.6.Supple9_99"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Hasegawa,                Y,              Hasegawa, T,                Takada, M,                Tsuchiya,            Y. Plasma free            insulin-like growth factor I concentrations in growth hormone deficiency in children and            adolescents. Eur J Endocrinol          1996;134: 184\u20139.","DOI":"10.1530\/eje.0.1340184"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Backeljauw,                P. Therapy            with recombinant human IGF-1 for children with primary insulin-like growth factor-I            deficiency. Growth Horm IGF Res          2020;51: 22\u20136.","DOI":"10.1016\/j.ghir.2020.01.001"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Lippe,              B, Frasier,                SD, Kaplan,                SA. Use of            growth hormone-gel. Arch Dis Child          1979;54: 609\u201313.","DOI":"10.1136\/adc.54.8.609"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Trivellin,                G, Daly,                AF, Faucz,                FR, Yuan,                B,                Rostomyan,              L, Larco,                DO, et al.            Gigantism and acromegaly due to Xq26 microduplications and GPR101            mutation. N Engl J Med          2014;371: 2363\u201374.","DOI":"10.1056\/NEJMoa1408028"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Cappola,                AR, Auchus,                RJ, El-Hajj                Fuleihan, G,                Handelsman,              DJ, Kalyani,                RR,              McClung, M,              et al. Hormones and aging: an endocrine            society scientific statement. J Clin Endocrinol Metab          2023;108: 1835\u201374.","DOI":"10.1210\/clinem\/dgad225"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Fares,              F, Guy,                R,              Bar-Ilan, A,                Felikman,            Y, Fima,                E. Designing            a long-acting human growth hormone (hGH) by fusing the carboxyl-terminal peptide of            human chorionic gonadotropin beta-subunit to the coding sequence of hGH.            Endocrinology          2010;151: 4410\u20137.","DOI":"10.1210\/en.2009-1431"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Kramer,              WG,                Jaron-Mendelson,              M, Koren,                R,                Hershkovitz,              O, Hart,                G.            Pharmacokinetics, pharmacodynamics, and safety of a long-acting human            growth hormone (MOD-4023) in healthy Japanese and caucasian adults.            Clin Pharmacol Drug Dev          2018;7: 554\u201363.","DOI":"10.1002\/cpdd.414"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Zelinska,                N, Iotova,                V,              Skorodok, J,                Malievsky,              O, Peterkova,                V,                Samsonova,              L, et al.            Long-acting C-terminal peptide-modified hGH (MOD-4023): results of a            safety and dose-finding study in GHD children. J Clin Endocrinol            Metab          2017;102: 1578\u201387.","DOI":"10.1210\/jc.2016-3547"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Horikawa,                R, Tanaka,                T,              Hasegawa, Y,                Yorifuji,            T, Ng,                D,                Rosenfeld,              RG, et al.            Efficacy and safety of once-weekly somatrogon compared with once-daily            somatropin (Genotropin\u00ae) in Japanese children with pediatric growth hormone deficiency:            results from a randomized phase 3 study. Horm Res            Paediatr          2022;95: 275\u201385.","DOI":"10.1159\/000524600"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Hershkovitz,                O,              Bar-Ilan, A,                Guy, R,                Felikman,            Y, Moschcovich,                L, Hwa,                V, et al.            In vitro and in vivo characterization of MOD-4023, a long-acting            carboxy-terminal peptide (CTP)-modified human growth hormone.            Mol Pharm          2016;13: 631\u20139.","DOI":"10.1021\/acs.molpharmaceut.5b00868"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Fares,              F, Havron,                A, Fima,                E. Designing            a long acting erythropoietin by fusing three carboxyl-terminal peptides of human            chorionic gonadotropin \u03b2 subunit to the N-terminal and C-terminal coding            sequence. Int J Cell Biol          2011;2011: 275063.","DOI":"10.1155\/2011\/275063"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Fares,              FA, Suganuma,                N,                Nishimori,              K, LaPolt,                PS, Hsueh,                AJ, Boime,                I. Design of            a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic            gonadotropin beta subunit to the follitropin beta subunit. Proc            Natl Acad Sci USA          1992;89: 4304\u20138.","DOI":"10.1073\/pnas.89.10.4304"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Deal,              CL, Steelman,                J,                Vlachopapadopoulou,              E, Stawerska,                R,                Silverman,              LA, Phillip,                M, et al.            Efficacy and safety of weekly somatrogon vs daily somatropin in children            with growth hormone deficiency: a phase 3 study. J Clin            Endocrinol Metab          2022;107: e2717\u201328.","DOI":"10.1210\/clinem\/dgac220"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Miller,              BS, Blair,                J,              Horikawa, R,                Linglart,            A, Yuen,                KCJ.            Developments in the management of growth hormone deficiency: clinical            utility of somapacitan. Drug Des Devel Ther          2024;18: 291\u2013306.","DOI":"10.2147\/DDDT.S315172"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Kildemoes,                RJ,                Backeljauw,              PF, H\u00f8jby,                M, Blair,                JC, Miller,                BS, Mori,                J, et al.            Model-based analysis of IGF-I response, dosing, and monitoring for            once-weekly somapacitan in children with GH deficiency. J Endocr            Soc          2023;7: bvad115.","DOI":"10.1210\/jendso\/bvad115"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Miller,              BS, Blair,                J,              Horikawa, R,                Linglart,            A, Yuen,                KCJ.            Developments in the management of growth hormone deficiency: clinical            utility of somapacitan. Drug Des Devel Ther          2024;18: 291\u2013306.","DOI":"10.2147\/DDDT.S315172"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. S\u00e4vendahl,                L,                Battelino,              T, Brod,                M, H\u00f8jby                Rasmussen, M,                Horikawa,            R, Juul,                RV, et al.            REAL 3 study group.Once-weekly somapacitan vs            daily GH in children with GH deficiency: results from a randomized phase 2            trial. J Clin Endocrinol Metab          2020;105: e1847\u201361.","DOI":"10.1210\/clinem\/dgaa614"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Mori,              J, Ohata,                Y,              Fujisawa, Y,                Sato, Y,                R\u00f6hrich, S,                Rasmussen,              MH, et al.            Effective growth hormone replacement with once-weekly somapacitan in            Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical            trial. Clin Endocrinol (Oxf)          2024;100: 389\u201398.","DOI":"10.1111\/cen.15025"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Manners,              A,                Korth-Bradley,              J, Wajnrajch,                MPA. A            randomized, cross-over study investigating the comparability of Somatrogon-ghla in 2            different drug product presentations. Clin Pharmacol Drug            Dev          2024;13: 1108\u201314;            Advance online publication.","DOI":"10.1002\/cpdd.1434"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Lau,              J, Bloch,                P,              Sch\u00e4ffer, L,                Pettersson,              I, Spetzler,                J, Kofoed,                J, et al.            Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue            semaglutide. J Med Chem          2015;58: 7370\u201380.","DOI":"10.1021\/acs.jmedchem.5b00726"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Knudsen,                LB, Lau,                J. The            discovery and development of liraglutide and semaglutide. Front            Endocrinol (Lausanne)          2019;10: 155.","DOI":"10.3389\/fendo.2019.00155"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Chatelain,                P,                Malievskiy,              O, Radziuk,                K,                Senatorova,              G, Abdou,                MO,                Vlachopapadopoulou,              E, et al.            TransCon GH Working Group.A randomized phase 2            study of long-acting TransCon GH vs daily GH in childhood GH deficiency.            J Clin Endocrinol Metab          2017;102: 1673\u201382.","DOI":"10.1210\/jc.2016-3776"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Sprog\u00f8e,              K, Mortensen,                E, Karpf,                DB, Leff,                JA. The            rationale and design of TransCon growth hormone for the treatment of growth hormone            deficiency. Endocr Connect          2017;6: R171\u201381.","DOI":"10.1530\/EC-17-0203"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Thornton,                PS,                Maniatis,              AK,                Aghajanova,              E, Chertok,                E,                Vlachopapadopoulou,              E, Lin,                Z, et al.            Weekly Lonapegsomatropin in treatment-na\u00efve children with growth hormone            deficiency: The phase 3 heiGHt trial. J Clin Endocrinol            Metab          2021;106: 3184\u201395.","DOI":"10.1210\/clinem\/dgab529"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Maniatis,                AK,              Casella, SJ,                Nadgir, UM,                Hofman, PL,                Saenger, P,                Chertock,              ED, et al.            Safety and Efficacy of Lonapegsomatropin in children with growth hormone            deficiency: enliGHten trial 2-year results. J Clin Endocrinol            Metab          2022;107: e2680\u20139.","DOI":"10.1210\/clinem\/dgac217"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Khan,              AA, Rejnmark,                L, Rubin,                M, Schwarz,                P, Vokes,                T, Clarke,                B, et al.            PaTH forward: a randomized, double-blind, placebo-controlled phase 2            trial of TransCon PTH in adult hypoparathyroidism. J Clin            Endocrinol Metab          2022;107: e372\u201385.","DOI":"10.1210\/clinem\/dgab577"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Savarirayan,                R,                Hoernschemeyer,              DG,              Ljungberg, M,                Zarate, YA,                Bacino, CA,                Bober, MB,              et al. Once-weekly TransCon CNP            (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre,            randomised, double-blind, placebo-controlled, dose-escalation trial.            EClinicalMedicine          2023;65: 102258.","DOI":"10.1016\/j.eclinm.2023.102258"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Kildemoes,                RJ,                Backeljauw,              PF, H\u00f8jby,                M, Blair,                JC, Miller,                BS, Mori,                J, et al.            Model-based analysis of IGF-I response, dosing, and monitoring for            once-weekly somapacitan in children with GH deficiency. J Endocr            Soc          2023;7: bvad115.","DOI":"10.1210\/jendso\/bvad115"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. J\u00f8rgensen,                JO, M\u00f8ller,                N,                Lauritzen,              T, Alberti,                KG, Orskov,                H,                Christiansen,              JS. Evening            versus morning injections of growth hormone (GH) in GH-deficient patients: effects on            24-hour patterns of circulating hormones and metabolites. J Clin            Endocrinol Metab          1990;70: 207\u201314.","DOI":"10.1210\/jcem-70-1-207"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75. Lin,              Z, Shu,                AD, Bach,                M, Miller,                BS, Rogol,                AD. Average            IGF-1 prediction for once-weekly Lonapegsomatropin in children with growth hormone            deficiency. J Endocr Soc          2021;6: bvab168.","DOI":"10.1210\/jendso\/bvab168"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. Fisher,              DM,              Rosenfeld,            RG,                Jaron-Mendelson,              M, Amitzi,                L, Koren,                R, Hart,                G.            Pharmacokinetic and pharmacodynamic modeling of MOD-4023, a long-acting            human growth hormone, in growth hormone deficiency children.            Horm Res Paediatr          2017;87: 324\u201332.","DOI":"10.1159\/000470842"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77. Key,              TJ, Appleby,                PN, Reeves,                GK, Roddam,                AW, Endogenous            Hormones and Breast Cancer Collaborative Group.Insulin-like            growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled            individual data analysis of 17 prospective studies. Lancet            Oncol          2010;11: 530\u201342.","DOI":"10.1016\/S1470-2045(10)70095-4"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Travis,              RC, Appleby,                PN, Martin,                RM, Holly,                JMP,                Albanes, D,                Black, A,              et al. A meta-analysis of individual            participant data reveals an association between circulating levels of IGF-I and prostate            cancer risk. Cancer Res          2016;76: 2288\u2013300.","DOI":"10.1158\/0008-5472.CAN-15-1551"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. Mukama,              T, Srour,                B, Johnson,                T, Katzke,                V, Kaaks,                R. IGF-1 and            risk of morbidity and mortality from cancer, cardiovascular diseases, and all causes in            EPIC-Heidelberg. J Clin Endocrinol Metab          2023;108: e1092\u2013105.","DOI":"10.1210\/clinem\/dgad212"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Gao,              X, Chen,                J, Cao,                B, Dou,                X, Peng,                Y, Su,                C, et al.            Correction: first clinical study on long-acting growth hormone therapy in            children with Turner sydrome. Horm Metab Res          2022;54: e5.","DOI":"10.1055\/a-2008-2304"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. Juul,              A,              Backeljauw,            P, H\u00f8jby,                M, Kawai,                M,                Kildemoes,              RJ, Linglart,                A, et al.            Somapacitan in children born small for gestational age: a multi-centre,            open-label, controlled phase 2 study. Eur J Endocrinol          2023;188: lvac008.","DOI":"10.1093\/ejendo\/lvac008"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. Gravholt,                CH, Viuff,                MH, Brun,                S,                Stochholm,              K, Andersen,                NH. Turner            syndrome: mechanisms and management. Nat Rev Endocrinol          2019;15: 601\u201314.","DOI":"10.1038\/s41574-019-0224-4"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83. Fiot,              E, Alauze,                B,                Donadille,              B,                Samara-Boustani,              D, Houang,                M, De                Filippo, G, et            al. Turner syndrome: French national diagnosis and            care protocol (NDCP; National Diagnosis and Care Protocol).            Orphanet J Rare Dis          2022;17(Suppl 1):            261.","DOI":"10.1186\/s13023-022-02423-5"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84. Wakeling,                EL,              Brioude, F,                Lokulo-Sodipe,              O, O\u2019Connell,                SM, Salem,                J, Bliek,                J, et al.            Diagnosis and management of Silver-Russell syndrome: first international            consensus statement. Nat Rev Endocrinol          2017;13: 105\u201324.","DOI":"10.1038\/nrendo.2016.138"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85. Luo,              X, Zhao,                S, Yang,                Y, Dong,                G, Chen,                L, Li,                P, et al.            Long-acting PEGylated growth hormone in children with idiopathic short            stature. Eur J Endocrinol          2022;187: 709\u201318.","DOI":"10.1530\/EJE-22-0449"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86. Choi,              HS, Kwon,                A, Suh,                J, Song,                K, Chae,                HW, Kim,                HS. Effect of            long-acting growth hormone treatment on endogenous growth hormone secretion in            prepubertal patients with idiopathic short stature: A preliminary study.            Growth Horm IGF Res          2022;66: 101486. Clinical            Trial.","DOI":"10.1016\/j.ghir.2022.101486"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87. Rapaport,                R, Wit,                JM, Savage,                MO. Growth            failure: \u2018idiopathic\u2019 only after a detailed diagnostic evaluation.            Endocr Connect          2021;10: R125\u201338.","DOI":"10.1530\/EC-20-0585"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88. Andrews,              A, Maharaj,                A,              Cottrell, E,                Chatterjee,              S, Shah,                P, Denvir,                L, et al.            Genetic characterization of short stature patients with overlapping            features of growth hormone insensitivity syndromes. J Clin            Endocrinol Metab          2021;106: e4716\u201333.","DOI":"10.1210\/clinem\/dgab437"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89. Busschbach,                JJ, Rikken,                B, Grobbee,                DE, De                Charro, FT,                Wit,            JM. Quality of            life in short adults. Horm Res          1998;49: 32\u20138.","DOI":"10.1159\/000023123"},{"key":"90","unstructured":"90. Gardner,              M, Scerbak,                T,              Sandberg,            DE. Psychosocial            aspects of short stature and rhGH treatment: implicit trends over 60+            years. Pediatr Endocrinol Rev          2018;16(Suppl 1):            129\u201341."},{"key":"91","doi-asserted-by":"crossref","unstructured":"91. Halas,              JG, Grimberg,                A. Dilemmas            of growth hormone treatment for GH deficiency and idiopathic short stature: defining,            distinguishing, and deciding. Minerva Pediatr          2020;72: 206\u201325.","DOI":"10.23736\/S0026-4946.20.05821-1"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92. Mameli,              C, Orso,                M,                Calcaterra,              V,              Wasniewska,              MG, Aversa,                T, Granato,                S, et al.            Efficacy, safety, quality of life, adherence and cost-effectiveness of            long-acting growth hormone replacement therapy compared to daily growth hormone in            children with growth hormone deficiency: A systematic review and            meta-analysis. Pharmacol Res          2023;193: 106805.","DOI":"10.1016\/j.phrs.2023.106805"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93. Backeljauw,                P, Cappa,                M, Kiess,                W, Law,                L, Cookson,                C, Sert,                C, et al.            Impact of short stature on quality of life: A systematic literature            review. Growth Horm IGF Res          2021;57-58: 101392.","DOI":"10.1016\/j.ghir.2021.101392"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94. Schumacher,                A. On the            significance of stature in human society. J Hum Evol          1982;11: 697\u2013701.","DOI":"10.1016\/S0047-2484(82)80058-4"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95. Tanaka,              T, Soneda,                S, Sato,                N, Kishi,                K, Noda,                M,                Ogasawara,              A, et al.            The boy:girl ratio of children diagnosed with growth hormone            deficiency-induced short stature is associated with the boy:girl ratio of children            visiting short stature clinics. Horm Res Paediatr          2021;94: 211\u20138.","DOI":"10.1159\/000518995"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96. Allen,              DB. Growth            promotion ethics and the challenge to resist cosmetic endocrinology.            Horm Res Paediatr          2017;87: 145\u201352.","DOI":"10.1159\/000458526"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97. Wit,              JM, Joustra,                SD.            Long-acting PEGylated growth hormone in children with idiopathic short            stature: time to reconsider our diagnostic and treatment            policy? Eur J Endocrinol          2023;188: lvac005.","DOI":"10.1093\/ejendo\/lvac005"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98. Rivolo,              S, Loftus,                J, Peter,                B, Fahey,                M,                Kongnakorn,              T.            Cost-effectiveness and cost-utility analysis of somatrogon once-weekly            injections vs. daily growth hormone injection for treating paediatric growth hormone            deficiency in Ireland. J Med Econ          2023;26: 963\u201372.","DOI":"10.1080\/13696998.2023.2228167"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99. Bright,              GM, Do,                MT, McKew,                JC, Blum,                WF,              Thorner,            MO. Development            of a predictive enrichment marker for the oral GH secretagogue LUM-201 in pediatric            growth hormone deficiency. J Endocr Soc          2021;5: bvab030.","DOI":"10.1210\/jendso\/bvab030"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100. Blum,              WF, Bright,                GM, Do,                MT, McKew,                JC, Chen,                H, Thorner,                MO.            Corroboration of height velocity prediction markers for rhGH with an oral            GH secretagogue treatment in children with GHD. J Endocr            Soc          2021;5: bvab029.","DOI":"10.1210\/jendso\/bvab029"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101. Codner,              E, Cassorla,                F,                Tiulpakov,              AN, Mericq,                MV, Avila,                A,                Pescovitz,              OH, et al.            Effects of oral administration of ibutamoren mesylate, a nonpeptide            growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in            growth hormone-deficient children. Clin Pharmacol Ther          2001;70: 91\u20138.","DOI":"10.1067\/mcp.2001.116514"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102. Nass,              R, Pezzoli,                SS,              Oliveri, MC,                Patrie, JT,                Harrell,            FE, Clasey,                JL, et al.            Effects of an oral ghrelin mimetic on body composition and clinical            outcomes in healthy older adults: a randomized trial. Ann Intern            Med          2008;149: 601\u201311.","DOI":"10.7326\/0003-4819-149-9-200811040-00003"},{"key":"103","unstructured":"103. www.endocrine.org\/podcast\/enp73-a-robotic-teriparatide-pill-to-treat-osteoporosis          (as of August 11th in 2024)."},{"key":"104","doi-asserted-by":"crossref","unstructured":"104. Tripto-Shkolnik,                L, Szalat,                A, Tsvetov,                G, Rouach,                V,                Sternberg,              C, Hoppe,                A, et al.            Oral daily PTH(1-34) tablets (EB613) in postmenopausal women with low BMD            or osteoporosis: a randomized, placebo-controlled, 6-month, phase 2            study. J Bone Miner Res          2024;39: 672\u201382.","DOI":"10.1093\/jbmr\/zjae057"},{"key":"105","unstructured":"105. www.kyowakirin.co.jp\/pressroom\/news_releases\/2024\/pdf\/20240207_01.pdf (in          Japanese) as of August 11<sup>th<\/sup> in 2024)."},{"key":"106","doi-asserted-by":"crossref","unstructured":"106. Javle,              M,                Roychowdhury,              S, Kelley,                RK,              Sadeghi, S,                Macarulla,              T, Weiss,                KH, et al.            Infigratinib (BGJ398) in previously treated patients with advanced or            metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from            a multicentre, open-label, single-arm, phase 2 study. Lancet            Gastroenterol Hepatol          2021<i>t<\/i>;6:            803\u201315.","DOI":"10.1016\/S2468-1253(21)00196-5"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107. Saitou,              H, Kitaoka,                T, Kubota,                T, Kanno,                J,                Mochizuki,              H, Michigami,                T, et al.            Clinical outcomes and medical management of achondroplasia in Japanese            children: A retrospective medical record review of clinical data.            Am J Med Genet A          2024;194: e63612.","DOI":"10.1002\/ajmg.a.63612"},{"key":"108","doi-asserted-by":"publisher","unstructured":"108. Savarirayan,                R, Tofts,                L, Irving,                M, Wilcox,                W, Bacino,                CA,                Hoover-Fong,              J, et al.            Once-daily, subcutaneous vosoritide therapy in children with            achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre            trial. Lancet          2020;396: 684\u201392.            Erratum in: Lancet 2020;396(10257):1070. doi: 10.1016\/S0140-6736(20)32074-2.            PMID: 32891212.","DOI":"10.1016\/S0140-6736(20)31541-5"}],"container-title":["Clinical Pediatric Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/cpe\/34\/1\/34_2024-0058\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T23:27:16Z","timestamp":1736551636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/cpe\/34\/1\/34_2024-0058\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":108,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1297\/cpe.2024-0058","relation":{},"ISSN":["0918-5739","1347-7358"],"issn-type":[{"value":"0918-5739","type":"print"},{"value":"1347-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"2024-0058"}}